``
HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 10, October 2018 – Next-generation biosensors - Transforming the delivery of healthcare       » China tops world in alcohol-related deaths       » First China-developed drug for colorectal cancer approved in China       » World's first shrimp genome may reveal why females are superior       » Tetris-like program could speed breast cancer detection       » Wearable patch to monitor blood pressure inside body      
INSIDE INDUSTRY
Typhoid vaccine prequalified
Typbar TCV from Bharat Biotech is the world鈥檚 first typhoid conjugate vaccine prequalified by WHO

WHO has prequalified the first conjugate vaccine to prevent typhoid fever called Typbar-TCV developed by Indian pharmaceutical company Bharat Biotech.

The vaccine has long-lasting immunity, requires only one dose and can be given to children as young as 6 months through routine childhood immunization programmes. Other typhoid vaccines are recommended for children over 2 years of age.

Prequalification by WHO means that the vaccine meets standards of quality, safety and efficacy, thus making it eligible for procurement by United Nations agencies, such as the United Nations Children鈥檚 Fund.

A conjugate vaccine is one that is composed of a polysaccharide antigen that is fused to a carrier molecule.

In October 2017, the Strategic Advisory Group of Experts (SAGE) on immunization, which advises WHO, recommended typhoid conjugate vaccine for routine use in children over six months of age in typhoid endemic countries.

SAGE also called for the introduction of typhoid conjugate vaccine to be prioritized for countries with the highest burden of typhoid disease or of antibiotic resistance to Salmonella Typhi, the bacterium that causes the disease.

Use of the vaccine should also help to curb the frequent use of antibiotics for treatment of presumed typhoid fever, and thus help slow the increase in antibiotic resistance in Salmonella Typhi.

Shortly after SAGE鈥檚 recommendation, Gavi鈥檚 board approved US$ 85 million in funding for typhoid conjugate vaccines starting in 2019.

Prequalification is a crucial step for making the vaccines available in low-income countries, while in countries that Gavi does not support, prequalification can help expedite licensure.

Global estimates of the typhoid burden range between 11 and 20 million cases and between about 128 000 and 161 000 typhoid deaths annually.

Click here for the complete issue.

NEWS CRUNCH  
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management - Technologies for biotech and pharmaceutical industries
August:
Regenerative technology - Meat of the future
September:
Doctor Robot - The digital healthcare revolution
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy